Dr. Franco researches the molecular basis of the differences between pediatric and adult onset thyroid cancer. She aims to understand how the tumor microenvironment impacts disease progression and response to therapy.
Dr. Maris investigates the molecular and genetic mechanisms contributing to the development and progression of neuroblastoma, a common childhood cancer. He also aims to develop new molecular diagnostic tests and less toxic, targeted therapies to treat relapsed or refractory neuroblastoma, including a major effort in immunotherapy discovery and development.
Dr. Ma focuses on immune engineering. He leverages genetic, chemistry, and engineering tools to dissect immune cell-cell and cell-tissue crosstalk and harness these crosstalk mechanisms to develop biomaterials, protein, and cell-based precision immunotherapies for cancer and autoimmune diseases.
Dr. Barret's research program focuses on immune function of children with cancer. His research involves investigating possible immune deficiencies that result in children developing cancer and developing immune-based therapies for childhood cancer.
Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.
Dr. Maude focuses on novel therapies for high-risk and relapsed pediatric acute lymphoblastic leukemia (ALL). She aims to identify new pediatric ALL treatments that are more effective, less toxic, and exhibit fewer side effects than existing cancer therapies.
Dr. Thomas-Tikhonenko has a long-standing interest in the pathobiology of solid and hematopoietic malignancies, in particular lymphomas and leukemias and other cancers driven by MYC overexpression. Within that research space, his studies focus mainly (but not exclusively) on RNA-based regulatory mechanisms, such as microRNAs and alternative mRNA splicing.
Dr. Balis's research focuses on the clinical pharmacology of anticancer drugs, new drug development, and clinical trial design and endpoints. He studies the pharmacokinetics and pharmacodynamics of anticancer drugs and has applied pharmacological principles to clinical trial design and clinical drug development. He is developing new biomarkers to serve as surrogate endpoints of drug toxicity or efficacy in clinical trials.
Dr. De Raedt researches pediatric high grade glioma development and aims to understand the involvement of crucial pathways. He investigates pathway interaction, and explores ways to develop therapies through analyzing human tumors, performing cellular studies, and developing accurate mouse models. This allows Dr. De Raedt and his team to perform novel pre-clinical studies that can lead to clinical trials.
Dr. Sgourakis’ research focuses on understanding the intricate molecular mechanisms that determine the vast repertoire of peptide antigens displayed by the proteins of the Major Histocompatibility Complex for immune surveillance by T cells and Natural Killer cells.